Back to Search Start Over

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation

Authors :
Yoshihiro Inamoto
Harry C. Schouten
Amin M. Alousi
Ravi Vij
David I. Marks
John E. Wagner
Joseph Pidala
Joseph H. Antin
Margaret L. MacMillan
Gérard Socié
Ayman Saad
Shahrukh K. Hashmi
Luciano J. Costa
Mukta Arora
Hisham Abdel-Azim
Hélène Schoemans
Michael T. Hemmer
Robert Peter Gale
Stephen R. Spellman
Daniel R. Couriel
Saurabh Chhabra
Taiga Nishihori
Sachiko Seo
Alvaro Urbano-Ispizua
Bipin N. Savani
Brenda W. Cooper
Muna Qayed
Robert J. Hayashi
Leo F. Verdonck
Mark R. Litzow
Jean A. Yared
Usama Gergis
Navneet S. Majhail
Betty K. Hamilton
Mahmoud Aljurf
Robert K. Stuart
Rammurti T. Kamble
Leslie Lehmann
Takanori Teshima
Ying Liu
Rodrigo Martino
Jean-Yves Cahn
Olle Ringdén
Peiman Hematti
Melhem Solh
Dennis Dong Hwan Kim
RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
Interne Geneeskunde
MUMC+: MA Hematologie (9)
Source :
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, Dipòsit Digital de la UB, Universidad de Barcelona, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, Biology of Blood and Marrow Transplantation, 25(1), 73-85. Elsevier Science, Recercat: Dipósit de la Recerca de Catalunya, Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya), Recercat. Dipósit de la Recerca de Catalunya
Publication Year :
2019

Abstract

The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. We evaluated 1564 adult patients who underwent RIC alloHCT for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS) from 2000 to 2013 using HLA-identical sibling (matched related donor [MRD]) or unrelated donor (URD) peripheral blood graft and received CYSP or TAC with MTX or MMF for GVHD prophylaxis. Primary outcomes of the study were acute and chronic GVHD and overall survival (OS). The study divided the patient population into 4 cohorts based on regimen: MMF-TAC, MMF-CYSP, MTX-TAC, and MTX-CYSP. In the URD group, MMF-CYSP was associated with increased risk of grade II to IV acute GVHD (relative risk [RR], 1.78; P < .001) and grade III to IV acute GVHD (RR, 1.93; P = .006) compared with MTX-TAC. In the URD group, use of MMF-TAC (versus MTX-TAC) lead to higher nonrelapse mortality. (hazard ratio, 1.48; P = .008). In either group, no there was no difference in chronic GVHD, disease-free survival, and OS among the GVHD prophylaxis regimens. For RIC alloHCT using MRD, there are no differences in outcomes based on GVHD prophylaxis. However, with URD RIC alloHCT, MMF-CYSP was inferior to MTX-based regimens for acute GVHD prevention, but all the regimens were equivalent in terms of chronic GVHD and OS. Prospective studies, targeting URD recipients are needed to confirm these results. ispartof: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION vol:25 issue:1 pages:73-85 ispartof: location:United States status: published

Details

Language :
English
ISSN :
10838791
Volume :
25
Issue :
1
Database :
OpenAIRE
Journal :
Biology of Blood and Marrow Transplantation
Accession number :
edsair.doi.dedup.....b57aec297a44430d0593c405a75fbaaf